RPCA
AMRX icon

Running Point Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Running Point Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$20K – 214
2022
Q3 		$20K Hold
10,000
– – 0.01% 180
2022
Q2 		$32K Hold
10,000
– – 0.02% 170
2022
Q1 		$42K Buy
+10,000
New +$44.3K 0.02% 164

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Running Point Capital Advisors's AMRX Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 10,000 shares — an estimated $20K sold.

Running Point Capital Advisors first reported a position in AMRX in Q1 2022 and held it in 3 quarters. The position peaked at $42K in Q1 2022. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Amneal Pharmaceuticals shares in Q4 2022, an estimated $20K.
  • Running Point Capital Advisors first reported a position in Amneal Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Amneal Pharmaceuticals position peaked at $42K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.